- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Who benefits from triple ruleout?
Two groups of patients do not benefit from a CTA scan to rule out coronary artery disease, pulmonary embolism, and aortic dissection-the so-called triple ruleout, according to Dr. U. Joseph Schoepf, director of CT research and development at Medical University of South Carolina. One comprises those who, based on clinical judgment, will leave the hospital. Scanning these people simply increases costs and radiation exposure. The other consists of those who have clear ECG signs or enzyme elevations for myocardial infarction.
Two groups of patients do not benefit from a CTA scan to rule out coronary artery disease, pulmonary embolism, and aortic dissection-the so-called triple ruleout, according to Dr. U. Joseph Schoepf, director of CT research and development at Medical University of South Carolina. One comprises those who, based on clinical judgment, will leave the hospital. Scanning these people simply increases costs and radiation exposure. The other consists of those who have clear ECG signs or enzyme elevations for myocardial infarction.
Where the triple ruleout is valuable is in the gray zone: patients who have acute coronary syndrome but whose presentation is not clear-cut. They may have a nondiagnostic ECG or markers that come back negative. Without the triple ruleout, these individuals would be admitted for an extended period of observation. They would undergo serial ECGs, serial enzyme tests, and possibly other nuclear medicine tests or catheter angiography.
"If the coronary CT is negative, we can conclude that it excludes significant artery disease as a cause of acute chest pain. The negative predictive value is as high as 98% to rule out stenosis. With 64-slice CT, we are more confident than ever," Schoepf said.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
